Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease ...(self-expanding stent as an alternative f...),Health

Date:10/23/2007

self-expanding stent as an alternative for patients evaluating treatment options for SFA disease," said co-principal investigator John R. Laird, M.D., Medical Director of the Vascular Center at the University of California, Davis Medical Center. "Millions of patients suffering from PAD are in need of a clinically proven therapy that will improve their quality of life, allow them to be more active and walk without pain."

"We are very pleased with the 12-month results of The RESILIENT Trial, which provide clinicians with the highest level of clinical data available for a therapy to treat PAD patients less invasively," said Stuart L. Foster, Edwards' corporate vice president, Critical Care and Vascular.

The LifeStent self-expanding nitinol stent is a percutaneously-delivered flexible mesh tube that expands when deployed to prop open a diseased vessel and is specifically designed to withstand bending and twisting of the SFA. In 2004, Edwards initiated The RESILIENT Trial enrolling 246 patients at 25 sites, including 134 LifeStent self-expanding stent patients randomized against 72 balloon angioplasty patients.

The SFA is the major artery providing blood flow to the leg and extends behind the knee as the popliteal artery. This is a common area of blockage, or significant narrowing of the artery, in patients who suffer from atherosclerosis of the lower extremities, causing moderate to severe pain due to poor blood flow in the leg muscles. It is estimated that approximately 8 million Americans suffer from lower-extremity PAD, which affects mostly men and women older than 50 years. Without an effective treatment, PAD can develop into critical limb ischemia, a severe obstruction of the arteries with decreased blood flow to the lower extremities that may result in amputation.

Edwards is currently in discussions with the U.S. Food and Drug Administration (FDA) for premarket approval of its LifeStent system with an SFA indication.

About Edwards Li
'/>"/>

SOURCE Edwards Lifesciences Corporation Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial